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Clinical optimism for dendritic cell vaccination against ovarian cancer has been tempered by
the knowledge that tumors avail themselves of multiple mechanisms of immune evasion,
thus blunting the efficacy of therapeutic vaccination. Mechanisms of immune suppression
include infiltration by regulatory T cells (Treg) and myeloid suppressor cell populations,
expression of co-inhibitory receptors, and expression of indoleamine 2,3-dioxygenase
(IDO). Expression of both B7-H1 and IDO are associated with differentiation and recruit-
ment of Treg, and clinical studies have shown that each of these mechanisms correlates
independently with increased morbidity and mortality in ovarian cancer patients. In sharp
contrast, recent studies have indicated that Th17 cell infiltration in ovarian cancer corre-
lates with improved patient outcomes and prolonged overall survival. Given that IDO plays
a pivotal role in the balance between Treg and Th17 immunity, elucidation of the mech-
anisms that regulate IDO activity and immune suppression may lead to novel adjuvants
to boost the clinical efficacy of dendritic cell vaccination against ovarian cancer and other
malignancies.
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THE CLINICAL PROBLEM
Clinical studies have shown that the immune system plays an active
and possible critical role in the pathogenesis of ovarian cancer, dis-
ease progression, and overall survival. Of the positive parameters,
CD3 T cell infiltration has been associated with prolonged survival
(1). A notable point from this investigation was that patients with
significant T cell infiltration in their tumors were more likely to
be optimally debulked during surgery provided an indication that
T cells may limit regional spread of the disease. In contrast with
these positive findings, the majority of studies have highlighted
multiple mechanisms of immune suppression that correlate with
poor patient outcomes in ovarian cancer.
Regulatory T cells (Treg) infiltration has been widely noted as
a negative correlate of clinical outcomes for many malignancies,
and ovarian cancer is no exception. Curiel and colleagues showed
that Treg infiltration in ovarian cancer correlates with a poor prog-
nosis and increased mortality (2). Other investigators have shown
that high expression of Foxp3 (a transcription factor associated
with a Treg phenotype) is an independent prognostic indicator
for reduced survival (3), and that a high CD8/Treg ratio is asso-
ciated with more favorable outcomes (4). Further mechanisms
that contribute to the immunosuppressed state include expres-
sion of PD-L1 (B7-H1), which can promote T cell anergy and
apoptosis through engagement of PD-1 expressed by effector T
cells (5, 6) and expression of indoleamine 2,3-dioxygenase (IDO).
Expression of both B7-H1 and IDO are associated with differen-
tiation and recruitment of Treg (7–9), and clinical studies have
shown that each of these mechanisms correlates independently
with increased morbidity and mortality in ovarian cancer patients
(10–12). Immune suppression in the tumor micro-environment
is also likely to present a formidable barrier to the clinical efficacy
of therapeutic tumor vaccination, including dendritic cell (DC)
vaccination.
In sharp contrast with the evidence that Treg infiltration is
associated with poor outcomes in ovarian cancer, Th17 T cell
infiltration correlates with more favorable clinical outcomes (13).
Furthermore, tumor-infiltrating Th17 cells were negatively asso-
ciated with Treg infiltration, suggesting a reciprocal relationship
between these subsets. These observations have led to the ques-
tion of whether therapeutic benefit would accrue from induction
or expansion of Th17 cells, either through DC vaccination, other
types of tumor vaccines or adoptive immunotherapy (14, 15).
CAN DENDRITIC CELLS STIMULATE TH17 RESPONSES
AGAINST OVARIAN CANCER?
The tumor micro-environment can modify DC function through
multiple mechanisms, usually resulting in inhibition of DC acti-
vation and maturation, and the induction of immunosuppressive
DC and related myeloid cell populations (16). Tumor inhibition of
DC function can also have an impact on therapeutic DC vaccines,
indicating the need for DC vaccines with the capability to redirect
T cell immunity from immune suppression to pro-inflammatory
anti-tumor responses. Several lines of evidence have pointed to
a crucial role for MAPK signaling pathways in regulation of pro-
inflammatory versus tolerogenic or immunosuppressive DC func-
tion. Notably, Jackson and colleagues demonstrated that blockade
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of MEK 1/2 and ERK MAPK signaling restores tumor-mediated
inhibition of DC function and promotes IL-12 production and
Th1 T cell responses, whereas inhibition of p38 MAPK increases
signal transduction through ERK 1/2 and blocks IL-12 produc-
tion (17). In similar vein, p38 MAPK signaling in DC up-regulates
IL-10 expression and induces tolerance in a mouse model of
melanoma, resulting in suppression of anti-tumor T cell response,
whereas inhibition of p38 signaling restored the ability of DC to
stimulate T cell responses (18). The observation that p38 inhibi-
tion or MEK/ERK activation restores DC function in myeloma
patients provides further evidence that p38 blockade may be of
therapeutic benefit (19).
With respect to the balance between Treg versus Th17 immu-
nity, studies in mice have shown that p38 inhibition attenuates
Treg induction by DC and enhances the efficacy of DC vaccina-
tion and anti-tumor immunity (20), whereas blockade of the ERK
pathway suppresses DC-driven Th17 responses (21). Collectively,
these results suggest that preferential signaling though the ERK
pathway may favor a switch from DC induction of Treg responses
to Th17 differentiation and expansion.
In humans, treatment of ovarian tumor antigen-loaded,
cytokine-matured DC with a combination of IL-15 and a p38
MAPK inhibitor offers potent synergy in antagonism of Treg
induction and redirection toward Th17 responses that correlate
with strong CD8+ CTL activation (22). Tumor antigen-specific
CD4+ T cells secreted high levels of IL-17 and showed reduced
expression of CTLA-4, PD-1, and Foxp3 following activation
with IL-15/p38 inhibitor-treated DC. It was further shown that
modulation of p38 MAPK signaling was associated with reduced
expression of PD-L1 (B7-H1), loss of IDO activity, and increased
phosphorylation of ERK1/2 MAPK. These observations afford an
opportunity to develop innovative DC vaccination strategies to
boost Th17 immunity in ovarian cancer patients.
IDO AND THE BALANCE OF POWER BETWEEN TREG AND
TH17 IMMUNITY
Several lines of investigation have pointed to a pivotal role for
IDO in directing Treg or Th17 responses in tumor immunity.
In humans, IDO-expressing mature DC induce proliferation of
CD4+CD25+Foxp3+ Treg (9) and parallel studies in mice have
shown that IDO activates Treg and inhibits their conversion to
Th17-like T cells (8, 23). The pathways involved in control of
Treg/Th17 differentiation by IDO have hitherto been obscure, but
recent studies have revealed a relationship between IDO function
and the aryl hydrocarbon receptor (AhR) on DC and T cells. Bind-
ing of the AhR promotes the generation of Treg (24–26) and AhR
ligand-specific interactions may control the balance between Treg
and Th17 differentiation (27, 28). Remarkably, the tryptophan
catabolite kynurenine produced by IDO is a natural ligand for
AhR (29, 30), thus creating a mechanism by which IDO promotes
generation of Treg.
The AhR is also expressed by DC, and is required for induction
of IDO expression, thus creating a feedback loop via kynurenine
that maintains DC regulatory function (31). DC from AhR−/−
mice lacked IDO and inhibited Treg development and promoted
Th17 generation from naïve T cells. Addition of exogenous kynure-
nine restored the generation of Foxp3+ Treg and diminished Th17
FIGURE 1 | SCF levels in primary ovarian tumor ascites fluids. Samples
from 14 patients with a confirmed diagnosis of epithelial ovarian cancer
were tested by ELISA.
differentiation, reinforcing the hypothesis that IDO, kynurenine,
and AhR regulate the balance between Treg and Th17 immunity.
The mechanisms by which IDO expression is regulated in
ovarian tumors and tumor-associated myeloid cells are largely
unknown. One potential mechanism is that IDO activity may be
driven by c-KIT signaling following binding of stem cell factor
(SCF), which is secreted by ovarian tumors (32–34). This proposal
is based in part on recent studies showing that IDO expression can
be blocked by inhibitors of c-KIT or mTOR (downstream of the
c-KIT-PI3K-AKT pathway), with resultant potentiation of anti-
tumor T cell responses (35). Furthermore, siRNA knockdown of
SCF or blockade of c-KIT can inhibit myeloid-derived suppres-
sor cell expansion, Treg development and tumor angiogenesis,
producing a synergistic therapeutic effect in combination with
immunotherapy (36). Given that SCF is abundantly present in
ovarian tumor ascites (Figure 1), these findings raise the possibil-
ity that similar mechanisms of immune regulation may prevail in
ovarian cancer.
Collectively, these observations allow formulation of an innov-
ative model in which SCF binds c-KIT expressed by ovarian tumor
cells or infiltrating myeloid cells, resulting in IDO expression.
Kynurenine produced by IDO activity binds AhR on T cells and
induces Treg differentiation (Figure 2). Drugs that block c-KIT
signaling or IDO function may inhibit Treg recruitment and alle-
viate immune suppression by shifting the balance in favor of Th17
T cell differentiation and expansion.
INNOVATIVE STRATEGIES FOR ALLEVIATION OF
IDO-MEDIATED IMMUNE SUPPRESSION
Although the ability to manipulate the functional plasticity of DC
to stimulate Th17 responses against ovarian tumor antigens rep-
resents a therapeutic opportunity, DC vaccination may not be
clinically effective in the face of substantial barriers imposed by
immune suppression in the tumor micro-environment. Direct
depletion of tumor-associated Treg has often been the favored
means of alleviating immune suppression in support of DC vacci-
nation or other tumor vaccine strategies. Depletion of Treg activity
may be achieved by treatment with low dose cyclophosphamide or
denileukin diftitox (ONTAK) (37, 38). The ability of cyclophos-
phamide to inhibit Treg and boost anti-tumor immunity has been
known for decades (39), and this drug is now widely used as an
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FIGURE 2 | A model for regulation of IDO expression andTreg/Th17
immunity in the ovarian tumor micro-environment. Tumor production of
SCF activates c-KIT signaling in TAM, leading to induction of IDO expression.
The tryptophan catabolite kynurenine binds AhR on T cells, which shifts the
Th17/Treg balance in favor of Treg generation. Kynurenine can also bind AhR
on myeloid cells, further inducing IDO expression through a feedback loop.
adjuvant to tumor vaccination in clinical trials. Recent studies have
shown that cyclophosphamide promotes Th17 responses in cancer
patients (40), lending further credence to its use as an adjuvant for
DC vaccination against ovarian cancer.
A more favorable and durable approach may be to alleviate
tumor-associated immune suppression through modulation of
myeloid cell function and/or inhibition of IDO. If we accept the
proposed model for regulation of IDO expression and Treg gen-
eration as a working hypothesis, we can infer that agents with the
ability to inhibit c-KIT/PI3K/AKT/mTOR signaling or otherwise
modify myeloid cell function may reduce IDO activity and inhibit
recruitment of Treg in the ovarian tumor micro-environment. Our
focus will be on drugs that are FDA-approved for other indica-
tions and have shown the ability to alleviate immune suppression
and/or boost the efficacy of tumor vaccines or immune therapy in
animal models. Promising candidates include imatinib mesylate,
sunitinib, temsirolimus, and zoledronate, all of which have signif-
icant potential as adjuvants for DC vaccination against ovarian
cancer.
Imatinib mesylate (Gleevec) binds BCR-ABL and c-KIT, and is
an effective treatment for BCR-ABL+ chronic myeloid leukemia.
More recent studies have shown that the therapeutic effect of ima-
tinib could also be attributed to immune response, overcoming
tumor-associated T cell tolerance and boosting vaccine efficacy
(41). Imatinib also decreased Treg frequencies and enhanced anti-
tumor immune responses to DC vaccination against imatinib-
resistant BCR-ABL-negative lymphoma (42), and was subse-
quently shown to activate CD8+ T cells and induce Treg apoptosis
in a gastrointestinal tumor model through c-KIT inhibition and
diminished IDO expression (35).
With respect to ovarian cancer, KIT ligand (SCF) is anti-
apoptotic and increases cisplatin resistance, whereas imatinib
induces apoptosis (43). Although imatinib has shown minimal
clinical benefit as a single agent in ovarian cancer (44, 45), it is well
tolerated, and its ability to inhibit c-KIT and block IDO expres-
sion (35) suggests imatinib has potential to alleviate immune
suppression as an adjuvant treatment for DC vaccination.
Sunitinib is an inhibitor of VEGFR, PDGFR, c-KIT, and Flt-3,
and is FDA-approved for metastatic renal cell cancer. Sunitinib is
currently being tested in over 300 clinical trials for cancer treat-
ment (46), including ovarian cancer (47, 48). Numerous studies
have shown that sunitinib can reduce myeloid suppressor cell accu-
mulation and decrease Treg frequencies in animal models (49, 50)
and in renal cell carcinoma patients (51, 52). This activity may
at least in part be mediated through c-KIT and/or STAT3 signal-
ing (49, 50). Sunitinib has been tested in combination with DC
loaded with autologous total tumor RNA in a recently completed
phase II clinical trial (NCT00678119), and a new phase III trial of
DC vaccination for renal cell carcinoma following first-line treat-
ment with sunitinib has recently been initiated (NCT01582672).
No results have been reported to date for either trial.
Axitinib, a related tyrosine kinase inhibitor that blocks multi-
ple targets, including c-KIT, may also have potential as adjuvant
therapy for DC vaccination. Axitinib was approved by the FDA in
2012, as a second line treatment for advanced renal cell carcinoma.
Rapamycin (an mTOR inhibitor) is well known for its ability to
suppress T cell responses, but it also has potential as an anticancer
agent through inhibition of HIF-1, HIF-2, and VEGF. mTOR is
a downstream component of the KIT-PI3K-AKT pathway, and
rapamycin can reproduce imatinib-mediated reduction of IDO
(35). Temsirolimus (a rapamycin analog) was FDA-approved for
the treatment of renal cancer in 2007, and is first-line treatment
for patients with metastatic disease. Remarkably, temsirolimus can
enhance the efficacy of tumor vaccines (53), suggesting that it does
not share the immunosuppressive properties of rapamycin, and
may have value as an adjuvant for DC vaccination.
Although they don’t act as inhibitors of c-KIT or downstream
signaling, amino-bisphosphonates may also have potential as adju-
vant treatments, by virtue of their ability to modify myeloid cell
function. Zoledronic acid is a matrix metalloprotease inhibitor
that blocks myeloid-derived suppressor cell expansion (54) and
induces a pro-inflammatory shift in macrophage function, favor-
ing M1 polarization over the pro-tumor M2 phenotype. Zole-
dronate can reduce expression of VEGF and IL-10 and increase
production of type-1 cytokines such as IFNγ (55, 56). It is not
known whether amino-bisphosphonates have any influence on
IDO expression.
DIRECT INHIBITION OF IDO
While it would appear reasonable to block IDO function directly,
rather than use signal transduction inhibitors that might lead
to off-target effects and toxicity, agents that inhibit IDO activity
are few and far between. 1-Methyl tryptophan has seen exten-
sive experimental use as a competitive blocker of IDO function
(57, 58), but its clinical use has been limited. There are cur-
rently two trials of DC vaccination combined with 1-methyl
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tryptophan listed by ClinicalTrials.gov: a phase I/II trial of ade-
novirus p53-transduced DC vaccine with 1-methyl tryptophan
for treatment of recurrent/stage IV breast cancer (NCT01042535,
sponsored by the National Cancer Institute), and a phase II trial of
Sipuleucel-T (Provenge®, Dendreon Corp.) with 1-methyl tryp-
tophan for treatment of metastatic castration-resistant prostate
cancer (NCT01560923, sponsored by the Masonic Cancer Center,
University of Minnesota).
A second agent, INCB24360, developed by Incyte Corporation,
is being tested in a phase II trial versus tamoxifen for patients
with ovarian, primary peritoneal, or fallopian tube cancer and
suffering biochemical recurrence, i.e., with CA125 at least twice
the upper limit of normal (NCT01685255). INCB24360 is also
being tested in a randomized phase II trial of ipilimumab plus
INCB24360 or placebo for metastatic melanoma (NCT01604889).
Should INCB24360 demonstrate efficacy in inhibition of IDO
activity in the clinical setting, it may have considerable value as
an adjuvant treatment for DC vaccination against ovarian cancer
and other malignancies.
CONCLUSION
Elucidation of the multiple facets of immune regulation in the
ovarian tumor micro-environment has sharpened the apprecia-
tion that there are formidable barriers to therapeutic DC vac-
cination, but has also raised the prospect for mechanism-based
interventions. The observations that Treg infiltration or Th17 infil-
tration respectively correlate with either diminished or improved
overall survival strongly indicate that blockade of Treg activity or
stimulation of Th17 responses could similarly result in improved
clinical outcomes. DC vaccine strategies that bias tumor-specific
T cell responses toward a Th17 phenotype should be tested in
clinical trials, preferably in advanced stage ovarian cancer patients
that have completed surgery and chemotherapy and have mini-
mal disease at the time of DC vaccination. The goal should be to
prevent disease recurrence or progression, rather than to use DC
vaccination as a salvage therapy in patients with significant tumor
burden.
Although DC vaccination designed to boost Th17 immu-
nity represents a step forward, adjuvant treatments that alleviate
tumor-associated immune suppression are probably essential for
any prospect of clinical success. IDO expression by ovarian tumor
cells or infiltrating myeloid cells arguably forms one of the corner-
stones of immune regulation in ovarian cancer, and it is no surprise
that high IDO expression is associated with diminished overall
survival. Drugs that block IDO expression or activity may tip
the Treg/Th17 balance in favor of anti-tumor immunity, and sev-
eral intriguing possibilities that are either FDA-approved for other
indications or are currently in clinical trials have been consid-
ered. Targeting of the IDO/kynurenine/AhR regulatory pathway
may also be an innovative approach, e.g., through the use of AhR
antagonists such as resveratrol.
Other treatments that can have an impact on immune reg-
ulation in ovarian cancer should also be considered, either as
stand-alone therapy or in combination with DC vaccination. Ipil-
imumab targets the T cell inhibitory molecule CTLA-4, which is
highly expressed by Treg, and is FDA-approved for treatment of
metastatic melanoma. There are many clinical trials in progress for
ipilimumab in treatment of other malignancies, including ovarian
cancer, but results have been variable and often discouraging. The
prospects might be better for anti-PD-1 antibodies or anti-PD-L1
antibodies, for which promising results have been reported from
clinical trials. Given that PD-L1 (B7-H1) expression is associated
with decreased overall survival in ovarian cancer, blockade of PD-
L1, or PD-1 may be an attractive option. Collectively, though,
it is our opinion that the weight of evidence points to IDO as
the focal target for immunological intervention in support of DC
vaccination against ovarian cancer.
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